Purpose: We developed and characterized by histopathology and immunohistochemistry a syngeneic murine bladder tumor model derived from the MB49 tumor cell line. Materials and Methods: Bladder tumor implantation was achieved by intravesical instillation of 5 x 10 5 MB49 tumor cells in C57BL/6 mice. A chemical lesion of the bladder was performed in order to promote intravesical tumor implantation. The bladder wall lesion was accomplished by transurethral instillation of silver nitrate (AgNO 3 ). After 15 days, the animals were Results: Twenty-nine out of 30 animals (96.7%) developed intravesical tumors in a 15-day period. Macroscopically, the mean bladder weight was 0.196g (0.069-0.538g), 10 to 15 times the normal bladder weight. The immunohistochemical Conclusions: cauterization is widely described in the literature for syngeneic orthotopic animal models, the technique described in this study represents an alternative for intravesical bladder tumor implantation. Moreover, the histopathology and immunohistochemical analysis of the murine bladder tumor model derived from the MB49 cell line showed a resemblance to human
INTRODUCTION
Animal models provide a system for understanding basicbiological questions. With animal models,adequate control of experimentaldesign is possible so that rigorous experiments can be performed to test various hypotheses . In the case of testing therapeutic mechanisms, it is important to select a model that is most analogous to the clinical setting so that observations can be readily transferred to clinical studies for validation (1).
A murine bladder tumor model may offer some of these characteristics, while having many controlled variables under laboratory conditions (2). This permits inference from experimental data, which can be helpful for clinical purposes. The murine bladder tumor models may be a xenograft model (in immucancer model (4), or a syngeneic animal model (5).
der cancer research has allowed the implantation of human carcinomas in an animal model. In addition, it has demonstrated the importance of the immune system, in particular as regards T lymphocytes, in anti-tumor activity (6).
The chemically induced models were achieved by administering carcinogens such as N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide (FANFT) in mice strain C57BL/6 (8) . Although adequate for immunotherapeutic testing, a long period of time was required for carcinogen-induced bladder tumor growth.
The syngeneic animal models were developed with the objective of improving immunotherapeutic studies (9). It is characterized by the transplantation of carcinogen-induced bladder cancer into syngeneic immunocompetent mice (5,10). This murine bladder tumor model has been considered appropriate for this purpose, as it permits the possibility of mimicking intravesical conditions. Moreover, research can be improved by testing local tumor response to drugs in an immunocompetent host (11). Implantation of syngeneic tumor cells can be made subcutaneously (heterotopic model) or by intravesical instillation (orthotopic model), in the anatomical site.
In this study, our aim was to characterize the syngeneic orthotopic murine bladder cancer model derived from the MB49 tumor cell line by histopathology and immunohistochemistry. We focused on the urothelial histogenesis of the murine tumor in order to demonstrate its similarities to the human bladder as an useful experimental bladder tumor model for drug testing and new immunotherapeutic alternatives. In addition, we demonstrate the feasibility of the implantation of the tumor cell line MB49 by the chemical lesion of the bladder using silver nitrate, as described previously by Luo et al. (12). Silver nitrate was chosen for this purpose due to its controlled and stable characteristics. Similar effects may be achieved using ethanol and poly-L-lysine, but this was not tested in this series.
The markers used for immunohistochemistry testing were cytokeratin 7, carcinoembrionic antigen, p53 and c-erbB2 oncoprotein, all commonly used for evaluating human bladder tumor.
MATERIALS AND METHODS
Animals -Eight-to 10-week-old female C57BL/6 mice, weighing 15-20g, were provided by the Bioterism Center of the university and maintained at our animal care facility for 1 week prior to use. The area at a controlled room temperature, with food and water ad libitum. The experiments were approved by the institution's Ethics Board Council.
Preparation of tumor cells -Syngeneic bladder tumor cell line MB49 was kindly provided by Dr. Yi Lou (University of Iowa, USA). The cells were maintained in vitro culture (DMEM, 10% FBS, 1% penicillin/streptomycin, at 37 o C and 5% CO 2 ). Tumor cells were harvested by trypsinization and suspended in DMEM without L-glutamine, FBS, and antibiotics. Viability was determined by trypan blue exclusion and only tumor cell suspensions with more than 90% viable cells were used for tumor implantation.
Intravesical tumor implantation -Mice were anesthetized by the intraperitoneal administration of ketamine/xylazine solution at a dose of 0.1 mL/10g catheter (Nipro R ) was inserted through the urethra into the bladder using an inert lubricant (sterile contact gel) ( Figure-1) . Then, in order to prepare the bladder for tumor implantation, a brief acid exposure, followed by alkaline neutralization, promoted a chemical lesion on the bladder wall, performed by intravesical instillation of l silver nitrate (AgNO 3 ). This promoted an adequate and controlled diffuse bladder wall lesion. After 10 seconds, the content was washed out by transurethral infusion of phosphate-buffered saline.
catheter was inserted in the urethra for intravesical instillation of MB49 cells. A cell suspension of MB49 tumor cells (5 x 10 5 cells in 0.1 mL 50% normal mouse serum) was instilled and retained for 2 hours by stitches.
The mice were evaluated on a daily basis for viability and gross hematuria. After 15 days, the 2 inhalation, examined macroscopically for intravesical tumor and individu--included and stained by hematoxylin and eosin . Immunohistochemistry was performed to characterize the immunophenotype and the antibodies used were -all produced by Dakocytomation, Glostrup, Denmark.
containing tumor were placed on adhesive-coated slides. In a heat antigen retrieval process the slides heated for 30 min. in the steamer. The slides were incubated overnight at 4ºC with the above antibodies. Labelled Streptavidin Biotin (LSAB; Dako Cytomaat room temperature, then the slides were rinsed with Tris-buffer for 5 min., incubated for a further 35 min.
water for 5 min. Color was developed by incubating the slides in 0.06% diaminobenzidine in PBS for 15 minutes, and the slides were rinsed in Tris-buffer and dehydrated, cover slipped, and reviewed under light microscope. Tissue sections of a bladder urothelial well as pulmonary adenocarcinoma positive for cytokeratin 7 and CEA were used as positive controls. For each case a negative control was applied by following antibody by PBS.
RESULTS
All the animals survived the surgical intervention, no transmural bladder injury or bladder perforation was observed. All animals, after 7 days, presented evident gross hematuria ( Figure-2 ), that and intense hematuria. Considering all the animals (30) that received intravesical instillation of MB49 Macroscopically the mean bladder weight was 0.196g (0.069-0.538g) in the tumor group, while a C57BL/6 mouse bladder weighs between 0.010g to 0.015g approximately. The tumor was represented by an usually solitary solid mass, growing inside the bladder, deeply red, soft and extremely bloody. There -croscopically, there was a high grade urothelial solid carcinoma composed of proliferation of large, cubic cells, arranged in solid nests, with round, hypercromatic nuclei and one or more nucleoli. Scattered giant, bizarre cells were seen in the tumor. The mitosis rate was invasive through the bladder wall, reaching the muscularis propria. No vascular invasion or periurothelium was evident, and no in situ carcinoma was
The immunohistochemical analysis showed cancer that affects humans. Although p53 expression is very common in urothelial cancer, due to p53 mutation, in the murine model it does not seem to be a part of the carcinogenesis since we were unable to detect p53 staining. Also, we used antibody 60% of human urothelial carcinomas. There was no The molecular evaluation of those two abnormalities among others should be the subject of our next study.
COMMENTS
As demonstrated above, the histological and immunohistochemical characteristics described in the murine bladder tumor model derived from the MB49 cell line mimics one of the main aspects of lamina propria. By producing a pathologically similar cancer to the human urothelial carcinoma, evidence from experimental research may become closer to data from human testing.
Considering the immunoregulatory mechanisms that participate in bladder tumor-host interac--tigation. Consequently, adequate local and systemic experimental environment model is required, allowing studies.
A murine bladder tumor model may offer some of these characteristics, while having many controlled variables under laboratory conditions. These factors permit inference from experimental data, which can be helpful for clinical purposes, specially considering safety issues.
topic tumor implantation, improvements have been made to avoid the variability of tumor cell adhesion to the bladder wall (5). Soloway et al. simulated a transurethral fulguration by cauterizing the murine bladder wall, creating conditions for tumor cells implantation (10). The development of this techniby transforming the orthotopic syngeneic bladder tumor model into a reliable tool for investigating tumor growth mechanisms and intravesical drug testing. Furthermore, the model closely resembles the clinical situation, making it very suitable for bladder cancer research.
The use of immunohistochemistry for accurate diagnosis of cancer has long been demonstrated (13). Determination of cytokeratins, in this situation, may be helpful in tumors poorly differentiated and for identifying the primary site of metastatic -tion on tumor progression, giving p53 expression (15,16).
The murine bladder tumor model not only creates adequate conditions for understanding tumor adhesion, proliferation and invasiveness, but also allows the development of a cancer with many similar histopathological characteristics to the human urothelial carcinoma, making it a valuable tool for anti-tumor drug testing, based on immune, viral or gene therapy(9,17,18). 
CONCLUSIONS
The tumor implantation procedures described herein provide a reproducible experimental bladder cancer model. The orthotopic murine model has an important role improving our knowledge of therapeutic the proper anatomical site.
In conclusion, the histopathology and immumodel derived from the MB49 cell line resembles the to make inferences about its behavior and response to different treatment regimes.
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by temporary stitches (presumably of the urethra).
The effectivity of the described technique is comparable to the previous model. The tumor take was almost 100% and all animals developed gross pulmonary metastases, which was 20-70% before, was not mentioned here.
CK7, and CEA expression in this model. Interestingly, be aware that this can also be due to antibody-related problems since immunohistochemistry staining prothan in human tissue. We have previously examined Ki-67 (TEC-3) expression and found in the tumors up to 70% positive cells (unpublished data).
In general, the molecular comparison between human bladder cancers and mouse models is very interesting since the results of therapeutic applications may be easier to interpret. As the authors point out further molecular evaluations are planned. It would be highly interesting to perform these evaluations also in an humanized immune incompetent (SCID or Nude) to transfer the intravesical model into SCID mice since most mice died after bladder wall coagulation. Maybe to better results.
Dr. Ingo Kausch
Department of Urology
EDITORIAL COMMENT
Bladder cancer is well suited for experimental therapies due to the isolated bladder cavity in which therapies can be given locally. By transurethral noninvasive surgery, bladder tumors can easily be monitored and biopsies taken for further analyses. These features are beginning to attract a number of drug developers and gene therapy. Bladder cancer is one of few cancers that have excellent orthotopic murine experimental models that are closely mimicking the clinical situabiology can be studied and tumor therapy can be given locally by instillation via cauterization of urethra just as in the patients. In the current issue, Chade et al. are describing a novel system to enhance tumor take in experimental bladder cancer using silver nitrate (AgNO 3 ) as well as giving further insights into the biology of murine bladder tumors by performing a histopathological evaluation.
The most common murine bladder cancer cell lines are the mouse bladder-49 (MB49) and the mouse bladder tumor-2 (MBT2) cells (1-3). These two mice, respectively. The cell lines are utilized to create subcutaneous, orthotopic or metastatic tumors. In one was used for tumor take. The electric pulse created a burn wound to which MB49 cells attached and formed tumors. In this model, the effect of Bacillus CalmetteGuérin (BCG) therapy has been extensively evaluated and immunological mechanisms found in this model have later been proven transferable to human systems a few drawbacks. The main issue is that it can be Further, this model does not give 100% tumor take which increases the number of mice needed per treatment group and may mask the true result in some treatment groups where differences are slim. Many groups have tried to obtain similar or better tumor take by chemical pretreatment of the bladder surface prior instillation of tumor cells. Agents tested are for example ethanol and poly-L-lysine (PLL) (2). Ethanol functions as an irritant and theoretically removes the mucin layer in the bladder thereby facilitating tumor take. The latter, PLL, is a polycathion that is thought to by its positive electrical charge become a bridge between the negatively charged urothelium and the tumor cells thereby aiding tumor attachment. PLL has so far been the only agent that repeatedly gives tumor take in all mice. In this issue, Chade et al has further improved the management of the orthotopic model via the use of AgNO 3 pretreatment of the bladders to irritate the bladder wall prior tumor cell instillation. The tumor take is similar to that of PLL but the model as such saves time since this agent only needs a few seconds of incubation compared to PLL that needs to be incubated in the bladder for 10-20 min. prior tumor The murine experimental MB49 model gives new insights to tumor progression, survival and immune escape in human bladder cancer. Currently, there are several novel therapies such as immune and gene therapy that are proven potent in the MB49 model and now translated into clinical Phase I and II trials. It is important to further investigate murine experimental models to simplify the techniques as well as to further enlighten biological phenomena that may be translated into human cancer and get us closer to better and more
